Infectious risks in patients treated with extracorporeal photopheresis for graft‐versus‐host disease: A retrospective cohort study
Journal of Clinical Apheresis · 2022-02 · 37 (1) · 106-116
DOI: 10.1002/jca.21957 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Clinical Apheresis, online erschienen am 30.12.2021. Verfasst von Ugo Thevenet und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Hematology and Cellular Therapy, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France. Hauptthemen laut MEDLINE: Photopheresis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Background
Infections are common with significant mortality and morbidity in patients with graft‐versus‐host disease (GvHD). Extracorporeal photopheresis (ECP) is an advantageous treatment option for patients with GvHD because it is not immunosuppressive. The objective of this study was to assess the rate of infections and to determine risk factors in patients with GvHD. Materials and Methods In a single‐center cohort, we retrospectively collected data on infectious episodes by evaluating the clinical records of patients with GvHD treated by ECP since 2011.
Results
A total of 47 patients were included in this study. At ECP initiation, there were 10 patients with acute GvHD and 37 with chronic GvHD. At the final follow‐up, 200 infectious episodes were diagnosed in 91.5% of patients with an average follow‐up of 25.9 months (ie, 1.97 infections per patient per year). Most episodes had positive outcomes as there was no death related to infections, and only six infections required long‐term treatment. Higher dose of corticosteroids at the initiation of ECP was significantly associated with a shorter onset of the first infection (hazard ratio [HR] = 2.05; 95% confidence interval [CI] [1.17, 3.57]; P = .013). Unrelated donor transplants were significantly associated with a lower rate of infection (HR = 0.61; 95% CI [0.39, 0.95]; P = .028).
Conclusion
The results of our study suggest that ECP is associated with a low infection rate and an optimal clinical efficacy. Thus, ECP is still a suitable treatment for GvHD. Yet, a future study with a larger cohort will be necessary to deepen the identification of risk factors for infection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Hematology and Cellular Therapy, Institut de Cancérologie Lucien Neuwirth, Saint-Priest-en-Jarez, France.
- Department of Internal Medicine, CHU de Saint-Étienne, Saint-Étienne, France.
ORCID-Profile: Elisabeth Daguenet
Zitieren
APA
Thevenet, U., Daguenet, E., Beszera, S. M., Cornillon, J., Tavernier, E., Schein, F., Honeyman, F., & Guyotat, D. (2022). Infectious risks in patients treated with extracorporeal photopheresis for graft‐versus‐host disease: A retrospective cohort study. Journal of Clinical Apheresis, 37(1), 106-116. https://doi.org/10.1002/jca.21957
Vancouver
Thevenet U, Daguenet E, Beszera SM, Cornillon J, Tavernier E, Schein F, et al. Infectious risks in patients treated with extracorporeal photopheresis for graft‐versus‐host disease: A retrospective cohort study. Journal of Clinical Apheresis. 2022;37(1):106-116. doi:10.1002/jca.21957
BibTeX
@article{Thevenet2022,
author = {Thevenet, Ugo and Daguenet, Elisabeth and Beszera, Silvia-Maria and Cornillon, Jérôme and Tavernier, Emmanuelle and Schein, Flora and Honeyman, Fressia and Guyotat, Denis},
title = {Infectious risks in patients treated with extracorporeal photopheresis for graft‐versus‐host disease: A retrospective cohort study},
journal = {Journal of Clinical Apheresis},
year = {2022},
volume = {37},
number = {1},
pages = {106--116},
doi = {10.1002/jca.21957}
}
EUVIMED